JP2019536740A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019536740A5 JP2019536740A5 JP2019515905A JP2019515905A JP2019536740A5 JP 2019536740 A5 JP2019536740 A5 JP 2019536740A5 JP 2019515905 A JP2019515905 A JP 2019515905A JP 2019515905 A JP2019515905 A JP 2019515905A JP 2019536740 A5 JP2019536740 A5 JP 2019536740A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- seq
- amino acid
- binding
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 CC[C@]1CC[C@](CN(C(C[C@@]2SCCC(N(C)[C@@](C)C(O[C@@](CC(N(*)c(cc(CC(C)=CC=C[C@]([C@@](C3)(N4)O)OC)cc5OC)c5Cl)=O)[C@]5(C)O[C@]5C[C@]3OC4=O)=O)=O)=O)C2=O)CC1 Chemical compound CC[C@]1CC[C@](CN(C(C[C@@]2SCCC(N(C)[C@@](C)C(O[C@@](CC(N(*)c(cc(CC(C)=CC=C[C@]([C@@](C3)(N4)O)OC)cc5OC)c5Cl)=O)[C@]5(C)O[C@]5C[C@]3OC4=O)=O)=O)=O)C2=O)CC1 0.000 description 1
- PLNMJXBWNJMINP-UHFFFAOYSA-N O=C(CC1)N(CC2CCCCC2)C1=O Chemical compound O=C(CC1)N(CC2CCCCC2)C1=O PLNMJXBWNJMINP-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662399249P | 2016-09-23 | 2016-09-23 | |
| US62/399,249 | 2016-09-23 | ||
| US201762558711P | 2017-09-14 | 2017-09-14 | |
| US62/558,711 | 2017-09-14 | ||
| PCT/US2017/053113 WO2018067331A1 (en) | 2016-09-23 | 2017-09-22 | Bi specific anti-muc16-cd3 antibodies and nti-muc16 drug conjugates |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019536740A JP2019536740A (ja) | 2019-12-19 |
| JP2019536740A5 true JP2019536740A5 (enExample) | 2020-11-05 |
| JP7066691B2 JP7066691B2 (ja) | 2022-05-13 |
Family
ID=60083442
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019515905A Active JP7066691B2 (ja) | 2016-09-23 | 2017-09-22 | 二重特異性抗ｍｕｃ１６－ｃｄ３抗体および抗ｍｕｃ１６薬物複合体 |
| JP2019515904A Active JP7066690B2 (ja) | 2016-09-23 | 2017-09-22 | 抗ｍｕｃ１６（ムチン１６）抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019515904A Active JP7066690B2 (ja) | 2016-09-23 | 2017-09-22 | 抗ｍｕｃ１６（ムチン１６）抗体 |
Country Status (29)
| Country | Link |
|---|---|
| US (4) | US10738130B2 (enExample) |
| EP (3) | EP3515946B1 (enExample) |
| JP (2) | JP7066691B2 (enExample) |
| KR (2) | KR102531251B1 (enExample) |
| CN (2) | CN110036032B (enExample) |
| AU (2) | AU2017331363B2 (enExample) |
| BR (2) | BR112019005697A2 (enExample) |
| CA (2) | CA3037738A1 (enExample) |
| CL (4) | CL2019000712A1 (enExample) |
| CO (1) | CO2019003967A2 (enExample) |
| DK (2) | DK3515487T5 (enExample) |
| ES (2) | ES2925563T3 (enExample) |
| FI (1) | FI3515487T3 (enExample) |
| HR (2) | HRP20231281T1 (enExample) |
| HU (2) | HUE059761T2 (enExample) |
| IL (2) | IL265309B2 (enExample) |
| LT (2) | LT3515946T (enExample) |
| MD (1) | MD3515487T2 (enExample) |
| MX (2) | MX2019003326A (enExample) |
| MY (2) | MY200230A (enExample) |
| NZ (2) | NZ751907A (enExample) |
| PH (2) | PH12019500550A1 (enExample) |
| PL (2) | PL3515946T3 (enExample) |
| PT (2) | PT3515946T (enExample) |
| RS (2) | RS64691B1 (enExample) |
| SI (2) | SI3515946T1 (enExample) |
| SM (2) | SMT202200359T1 (enExample) |
| WO (2) | WO2018067331A1 (enExample) |
| ZA (2) | ZA201901557B (enExample) |
Families Citing this family (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI682941B (zh) | 2013-02-01 | 2020-01-21 | 美商再生元醫藥公司 | 含嵌合恆定區之抗體 |
| EP3277725B1 (en) | 2015-03-30 | 2020-11-25 | Regeneron Pharmaceuticals, Inc. | Heavy chain constant regions with reduced binding to fc gamma receptors |
| TWI744242B (zh) | 2015-07-31 | 2021-11-01 | 德商安美基研究（慕尼黑）公司 | Egfrviii及cd3抗體構築體 |
| TWI829617B (zh) | 2015-07-31 | 2024-01-21 | 德商安美基研究（慕尼黑）公司 | Ｆｌｔ３及ｃｄ３抗體構築體 |
| TWI796283B (zh) | 2015-07-31 | 2023-03-21 | 德商安美基研究（慕尼黑）公司 | Ｍｓｌｎ及ｃｄ３抗體構築體 |
| EA039859B1 (ru) | 2015-07-31 | 2022-03-21 | Эмджен Рисерч (Мюник) Гмбх | Биспецифические конструкты антител, связывающие egfrviii и cd3 |
| KR102777500B1 (ko) * | 2015-09-23 | 2025-03-11 | 리제너론 파아마슈티컬스, 인크. | 최적화된 항-cd3 이중특이적 항체 및 이의 용도 |
| US11583593B2 (en) | 2016-01-14 | 2023-02-21 | Synthis Therapeutics, Inc. | Antibody-ALK5 inhibitor conjugates and their uses |
| PL3411404T3 (pl) | 2016-02-03 | 2023-02-13 | Amgen Research (Munich) Gmbh | Konstrukty dwuswoistych przeciwciał wobec PSMA i CD3 angażujących komórki T |
| IL265309B2 (en) | 2016-09-23 | 2024-04-01 | Regeneron Pharma | Bispecific anti-muc16 antibodies and anti-muc16 antibodies for use in treating cancer |
| BR112019016336A2 (pt) * | 2017-02-10 | 2020-03-31 | Regeneron Pharmaceuticals, Inc. | Conjugado de anticorpo radiorrotulado, método para imageamento de um tecido que expressa lag3 e para tratar um tumor, e, composto. |
| RU2747095C2 (ru) * | 2018-05-11 | 2021-04-26 | Федеральное государственное бюджетное учреждение "Российский научный центр рентгенорадиологии" Министерства здравоохранения российской федерации (ФГБУ "РНЦРР" Минздрава России) | Мономолекулярный химерный т-клеточный рецептор к раковому антигену са125 |
| CN108659131B (zh) * | 2018-05-28 | 2021-09-14 | 长春力太生物技术有限公司 | 一种抗ceacam-5的单域抗体及其应用 |
| CN112351820B (zh) | 2018-06-21 | 2024-10-11 | 瑞泽恩制药公司 | 双特异性抗psma x抗cd28抗体及其用途 |
| TWI890661B (zh) * | 2018-06-21 | 2025-07-21 | 美商再生元醫藥公司 | 用雙特異性抗CD3xMUC16抗體及抗PD-1抗體治療癌症的方法 |
| TWI838389B (zh) * | 2018-07-19 | 2024-04-11 | 美商再生元醫藥公司 | 雙特異性抗-BCMAｘ抗-CD3抗體及其用途 |
| SG11202100221VA (en) | 2018-07-19 | 2021-02-25 | Regeneron Pharma | Chimeric antigen receptors with bcma specificity and uses thereof |
| US11578127B2 (en) | 2018-08-23 | 2023-02-14 | Regeneron Pharmaceuticals, Inc. | Anti-Fc epsilon-R1 alpha (FcεR1α) antibodies, bispecific antigen-binding molecules that bind FcεR1α and CD3, and uses thereof |
| MA53495A (fr) | 2018-08-31 | 2021-12-08 | Regeneron Pharma | Stratégie de dosage permettant d'atténuer le syndrome de libération de cytokines pour des anticorps bispécifiques cd3/c20 |
| AU2019369421A1 (en) | 2018-10-31 | 2021-06-03 | Regeneron Pharmaceuticals, Inc. | Method and system of identifying and quantifying a protein |
| WO2020102555A1 (en) * | 2018-11-16 | 2020-05-22 | Memorial Sloan Kettering Cancer Center | Antibodies to mucin-16 and methods of use thereof |
| US11249089B2 (en) | 2018-12-12 | 2022-02-15 | Regeneron Pharmaceuticals, Inc. | System and method of analysis of a protein using liquid chromatography-mass spectrometry |
| SG11202105948TA (en) | 2018-12-19 | 2021-07-29 | Regeneron Pharma | Bispecific anti-muc16 x anti-cd28 antibodies and uses thereof |
| CN113164598B (zh) | 2018-12-19 | 2025-04-25 | 里珍纳龙药品有限公司 | 双特异性抗cd28 x抗cd22抗体以及其用途 |
| EP3941941A1 (en) | 2019-03-22 | 2022-01-26 | Regeneron Pharmaceuticals, Inc. | Egfr x cd28 multispecific antibodies |
| WO2020227538A1 (en) * | 2019-05-08 | 2020-11-12 | Memorial Sloan Kettering Cancer Center | Humanized antibodies to mucin-16 and methods of use thereof |
| WO2020256721A1 (en) * | 2019-06-19 | 2020-12-24 | Synthis, Llc | Antib0dy-alk5 inhibitor conjugates and their uses |
| MA56537A (fr) * | 2019-06-21 | 2022-04-27 | Regeneron Pharma | Utilisation de molécules de liaison à l'antigène bispécifiques qui se lient à muc16 et cd3 en combinaison avec une co-stimulation de 4-1bb |
| CN114401988A (zh) * | 2019-07-09 | 2022-04-26 | 国家生物技术研究所公司 | 具有降低的免疫原性的抗体 |
| CN119954933A (zh) * | 2019-08-15 | 2025-05-09 | 瑞泽恩制药公司 | 用于细胞靶向的多特异性抗原结合分子及其用途 |
| CN112969715B (zh) * | 2019-08-21 | 2022-03-18 | 和铂医药(上海)有限责任公司 | 一种抗cd47抗原结合蛋白及其应用 |
| US11814428B2 (en) * | 2019-09-19 | 2023-11-14 | Regeneron Pharmaceuticals, Inc. | Anti-PTCRA antibody-drug conjugates and uses thereof |
| IL293288A (en) | 2019-12-06 | 2022-07-01 | Regeneron Pharma | Methods for the treatment of multiple myeloma with bispecific anti-bcma and anti-cd3 antibodies |
| TW202128991A (zh) | 2019-12-06 | 2021-08-01 | 美商再生元醫藥公司 | 抗ｖｅｇｆ蛋白組成物及其製備方法 |
| KR20210095781A (ko) | 2020-01-24 | 2021-08-03 | 주식회사 에이프릴바이오 | 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물 |
| JP2023525034A (ja) | 2020-05-08 | 2023-06-14 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Ｖｅｇｆトラップおよびミニトラップならびに眼障害およびがんの治療方法 |
| AU2021409785A1 (en) * | 2020-12-22 | 2023-07-06 | Amgen Inc. | Diffusion gradient assay for anti-cd3-containing molecules |
| FI4284512T3 (fi) | 2021-01-28 | 2025-05-22 | Regeneron Pharma | Koostumuksia ja menetelmiä sytokiinien vapautumisoireyhtymän hoitamiseksi |
| TW202304507A (zh) | 2021-04-02 | 2023-02-01 | 美商再生元醫藥公司 | 含有抗ｍｕｃ１６ｘ抗ｃｄ３雙特異性抗體之穩定調配物 |
| JP2024523033A (ja) | 2021-06-17 | 2024-06-25 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規の三重特異的結合分子 |
| IL312813A (en) | 2021-11-24 | 2024-07-01 | Regeneron Pharma | Methods for treating cancer using bispecific antibodies against CD3 and MUC16 and antibodies against CTLA-4 |
| AU2023204751A1 (en) | 2022-01-07 | 2024-07-11 | Regeneron Pharmaceuticals, Inc. | Methods of treating recurrent ovarian cancer with bispecific anti-muc16 x anti-cd3 antibodies alone or in combination with anti-pd-1 antibodies |
| AU2023205776A1 (en) * | 2022-01-10 | 2024-08-08 | Regeneron Pharmaceuticals, Inc. | Muc16 chimeric antigen receptors |
| JP2025504795A (ja) * | 2022-01-10 | 2025-02-19 | ナンチン リーズ バイオラブス カンパニー，リミティド | 抗体及びその用途 |
| IL315405A (en) | 2022-03-17 | 2024-11-01 | Regeneron Pharma | Methods for treating recurrent epithelioid sarcoma using bispecific anti-MUC16 and anti-CD3 antibodies alone or in combination with anti-PD-1 antibodies |
| AU2023254191A1 (en) | 2022-04-11 | 2024-10-17 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for universal tumor cell killing |
| CN120152994A (zh) * | 2022-09-06 | 2025-06-13 | 天境生物科技(上海)有限公司 | 多特异性构建体及其用途 |
| WO2024123698A1 (en) | 2022-12-08 | 2024-06-13 | Regeneron Pharmaceuticals, Inc. | Methods to characterizing a fragment crystallizable domain of a bispecific antibody |
| EP4665385A2 (en) | 2023-02-17 | 2025-12-24 | Regeneron Pharmaceuticals, Inc. | Induced nk cells responsive to cd3/taa bispecific antibodies |
| WO2024191983A1 (en) | 2023-03-13 | 2024-09-19 | Regeneron Pharmaceuticals, Inc. | Methods of treating cancer with bispecific anti-cd22 x anti-cd28 molecules |
| UY40783A (es) | 2023-06-12 | 2024-12-31 | Amgen Inc | Proteínas de unión a agonistas del receptor beta de linfotoxina |
| TW202519547A (zh) | 2023-07-10 | 2025-05-16 | 美商再生元醫藥公司 | 雙特異性PD-L1x4-1BB抗體及其使用方法 |
| WO2025014913A1 (en) | 2023-07-10 | 2025-01-16 | Regeneron Pharmaceuticals, Inc. | Bispecific pd-l1xcd28 antibodies and methods of use thereof |
| WO2025036848A1 (en) | 2023-08-11 | 2025-02-20 | Wuxi Biologics (Shanghai) Co., Ltd. | Anti-muc16 antibodies and uses thereof |
| CN117024596B (zh) * | 2023-08-18 | 2024-02-27 | 镜像绮点(上海)细胞技术有限公司 | 肿瘤原代细胞特异性标记与活体成像 |
| WO2025080540A1 (en) | 2023-10-09 | 2025-04-17 | Regeneron Pharmaceuticals, Inc. | Methods of treating cancer with a combination of a taaxcd3 bispecific antibody and a targeted immunocytokine |
| CN119978126A (zh) * | 2023-11-10 | 2025-05-13 | 深圳市菲鹏生物治疗股份有限公司 | 抗muc16抗体、靶向muc16的嵌合抗原受体及其应用 |
| TW202523694A (zh) * | 2023-11-17 | 2025-06-16 | 中國大陸商上海藥明生物技術有限公司 | 抗muc16抗體及其用途 |
| TW202539732A (zh) | 2023-11-29 | 2025-10-16 | 美商再生元醫藥公司 | 以雙特異性抗muc16×抗cd28抗體與抗pd-1抗體之組合或與雙特異性抗muc16×抗cd3抗體之組合治療復發性卵巢癌及子宮內膜癌之方法 |
| WO2025128652A1 (en) | 2023-12-12 | 2025-06-19 | Regeneron Pharmaceuticals, Inc. | Methods of treating endometrial cancer with bispecific anti-muc16 x anti-cd3 antibodies alone or in combination with anti-pd-1 antibodies |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| AU675916B2 (en) | 1991-06-14 | 1997-02-27 | Genentech Inc. | Method for making humanized antibodies |
| US5714586A (en) | 1995-06-07 | 1998-02-03 | American Cyanamid Company | Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates |
| US7087411B2 (en) | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
| US20070258987A1 (en) | 2000-11-28 | 2007-11-08 | Seattle Genetics, Inc. | Recombinant Anti-Cd30 Antibodies and Uses Thereof |
| CA2443617C (en) | 2001-04-17 | 2013-12-10 | The Board Of Trustees Of The University Of Arkansas | Repeat sequences of the ca125 gene and their use for diagnostic and therapeutic interventions |
| DE50105971D1 (de) | 2001-12-04 | 2005-05-25 | Brahms Ag | Verfahren zur Diagnose von Sepsis unter Bestimmung von CA 125 |
| EP2891666B1 (en) | 2002-10-16 | 2017-06-28 | Purdue Pharma L.P. | Antibodies that bind cell-associated CA 125/O722P and methods of use thereof |
| DK1629011T3 (da) | 2003-05-31 | 2010-05-03 | Micromet Ag | Humane anti-humane-DC3-bindingsmolekyler |
| EP1718667B1 (en) | 2004-02-23 | 2013-01-09 | Genentech, Inc. | Heterocyclic self-immolative linkers and conjugates |
| AR048098A1 (es) | 2004-03-15 | 2006-03-29 | Wyeth Corp | Conjugados de caliqueamicina |
| US7750116B1 (en) | 2006-02-18 | 2010-07-06 | Seattle Genetics, Inc. | Antibody drug conjugate metabolites |
| SI2374818T1 (sl) | 2006-06-02 | 2013-03-29 | Regeneron Pharmaceuticals, Inc. | Visokoafinitetna protitelesa za humani IL-6 receptor |
| RU2448979C2 (ru) | 2006-12-14 | 2012-04-27 | Ридженерон Фармасьютикалз, Инк. | Антитела человека к дельта-подобному лиганду-4 человека |
| WO2008122039A2 (en) | 2007-04-02 | 2008-10-09 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Selenocysteine mediated hybrid antibody molecules |
| CN101687037B (zh) | 2007-05-08 | 2013-07-10 | 健泰科生物技术公司 | 半胱氨酸改造的抗muc16抗体和抗体药物偶联物 |
| EP2167963B1 (en) | 2007-05-23 | 2019-04-17 | Ventana Medical Systems, Inc. | Polymeric carriers for immunohistochemistry and in situ hybridization |
| US8187801B2 (en) | 2008-04-24 | 2012-05-29 | Wisconsin Alumni Research Foundation | Methods and kits to detect and monitor ovarian cancer and preeclampsia |
| UA108598C2 (xx) | 2008-04-30 | 2015-05-25 | Високоефективні кон'югати та гідрофільні зшиваючі агенти (лінкери) | |
| AU2009275358C1 (en) | 2008-07-21 | 2015-09-24 | Polytherics Limited | Novel reagents and method for conjugating biological molecules |
| MY199658A (en) | 2009-06-26 | 2023-11-14 | Regeneron Pharma | Readily isolated bispecific antibodies with native immunoglobulin format |
| JO3182B1 (ar) | 2009-07-29 | 2018-03-08 | Regeneron Pharma | مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2 |
| CA2770617C (en) | 2009-08-10 | 2018-02-20 | Mark Smith | Reversible covalent linkage of functional molecules |
| SG10201913463QA (en) | 2010-02-08 | 2020-03-30 | Regeneron Pharma | Common light chain mouse |
| WO2011119979A2 (en) | 2010-03-26 | 2011-09-29 | Memorial Sloan-Kettering Cancer Center | Antibodies to muc16 and methods of use thereof |
| NZ602241A (en) | 2010-04-15 | 2015-03-27 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
| US20130244905A1 (en) | 2010-07-06 | 2013-09-19 | Ed Grabczyk | Reporter for RNA Polymerase II Termination |
| CN103338751A (zh) * | 2010-11-26 | 2013-10-02 | 约翰内斯堡威特沃特斯兰德大学 | 一种药物组合物 |
| SG195183A1 (en) | 2011-05-27 | 2013-12-30 | Ambrx Inc | Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives |
| US8815226B2 (en) | 2011-06-10 | 2014-08-26 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
| CN103997893B (zh) | 2011-10-14 | 2019-04-12 | 西雅图基因公司 | 吡咯并苯并二氮杂卓和靶向结合物 |
| BR112014008888A2 (pt) | 2011-10-14 | 2017-04-18 | Seattle Genetics Inc | pirrolobenzodiazepinas |
| BR112014009070B1 (pt) | 2011-10-14 | 2021-11-23 | Medimmune Limited | Método de síntese e intermediários úteis na preparação de pirrolobenzo-diazepinas |
| CN103987384A (zh) | 2011-10-14 | 2014-08-13 | 西雅图基因公司 | 吡咯并苯并二氮杂卓和靶向结合物 |
| WO2013068874A1 (en) | 2011-11-11 | 2013-05-16 | Pfizer Inc. | Antibody-drug conjugates |
| US20130224228A1 (en) | 2011-12-05 | 2013-08-29 | Igenica, Inc. | Antibody-Drug Conjugates and Related Compounds, Compositions, and Methods |
| JOP20200236A1 (ar) | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
| TWI682941B (zh) | 2013-02-01 | 2020-01-21 | 美商再生元醫藥公司 | 含嵌合恆定區之抗體 |
| MA38496B2 (fr) | 2013-03-15 | 2021-01-29 | Regeneron Pharma | Molécules biologiquement actives, leurs conjugués, et utilisations thérapeutiques |
| WO2015031396A1 (en) | 2013-08-26 | 2015-03-05 | Regeneron Pharmaceuticals, Inc. | Pharmaceutical compositions comprising macrolide diastereomers, methods of their synthesis and therapeutic uses |
| JP6449295B2 (ja) * | 2013-12-17 | 2019-01-09 | ジェネンテック， インコーポレイテッド | 抗ｃｄ３抗体および使用方法 |
| TWI754319B (zh) * | 2014-03-19 | 2022-02-01 | 美商再生元醫藥公司 | 用於腫瘤治療之方法及抗體組成物 |
| IL296062A (en) * | 2015-03-17 | 2022-10-01 | Memorial Sloan Kettering Cancer Center | Anti-muc16 antibodies and uses thereof |
| KR20240142591A (ko) | 2015-03-27 | 2024-09-30 | 리제너론 파아마슈티컬스, 인크. | 메이탄시노이드 유도체, 이의 컨주게이트, 및 사용 방법 |
| KR102777500B1 (ko) | 2015-09-23 | 2025-03-11 | 리제너론 파아마슈티컬스, 인크. | 최적화된 항-cd3 이중특이적 항체 및 이의 용도 |
| IL265309B2 (en) | 2016-09-23 | 2024-04-01 | Regeneron Pharma | Bispecific anti-muc16 antibodies and anti-muc16 antibodies for use in treating cancer |
-
2017
- 2017-09-22 IL IL265309A patent/IL265309B2/en unknown
- 2017-09-22 LT LTEPPCT/US2017/053114T patent/LT3515946T/lt unknown
- 2017-09-22 NZ NZ751907A patent/NZ751907A/en unknown
- 2017-09-22 RS RS20230945A patent/RS64691B1/sr unknown
- 2017-09-22 SI SI201731189T patent/SI3515946T1/sl unknown
- 2017-09-22 MY MYPI2019001374A patent/MY200230A/en unknown
- 2017-09-22 KR KR1020197010783A patent/KR102531251B1/ko active Active
- 2017-09-22 DK DK17784089.9T patent/DK3515487T5/da active
- 2017-09-22 ES ES17787989T patent/ES2925563T3/es active Active
- 2017-09-22 BR BR112019005697A patent/BR112019005697A2/pt unknown
- 2017-09-22 MX MX2019003326A patent/MX2019003326A/es unknown
- 2017-09-22 HU HUE17787989A patent/HUE059761T2/hu unknown
- 2017-09-22 LT LTEPPCT/US2017/053113T patent/LT3515487T/lt unknown
- 2017-09-22 HU HUE17784089A patent/HUE063020T2/hu unknown
- 2017-09-22 HR HRP20231281TT patent/HRP20231281T1/hr unknown
- 2017-09-22 PT PT177879897T patent/PT3515946T/pt unknown
- 2017-09-22 CA CA3037738A patent/CA3037738A1/en active Pending
- 2017-09-22 MY MYPI2019001357A patent/MY194596A/en unknown
- 2017-09-22 RS RS20220906A patent/RS63660B1/sr unknown
- 2017-09-22 US US15/713,574 patent/US10738130B2/en active Active
- 2017-09-22 SM SM20220359T patent/SMT202200359T1/it unknown
- 2017-09-22 CN CN201780071820.1A patent/CN110036032B/zh active Active
- 2017-09-22 BR BR112019005670A patent/BR112019005670A2/pt unknown
- 2017-09-22 US US15/713,578 patent/US10941208B2/en active Active
- 2017-09-22 EP EP17787989.7A patent/EP3515946B1/en active Active
- 2017-09-22 SI SI201731387T patent/SI3515487T1/sl unknown
- 2017-09-22 HR HRP20221202TT patent/HRP20221202T1/hr unknown
- 2017-09-22 AU AU2017331363A patent/AU2017331363B2/en active Active
- 2017-09-22 CN CN201780067123.9A patent/CN110214026B/zh active Active
- 2017-09-22 MX MX2019003322A patent/MX2019003322A/es unknown
- 2017-09-22 WO PCT/US2017/053113 patent/WO2018067331A1/en not_active Ceased
- 2017-09-22 CA CA3037536A patent/CA3037536A1/en active Pending
- 2017-09-22 NZ NZ751903A patent/NZ751903A/en unknown
- 2017-09-22 EP EP23182446.7A patent/EP4273172A3/en active Pending
- 2017-09-22 EP EP17784089.9A patent/EP3515487B1/en active Active
- 2017-09-22 SM SM20230308T patent/SMT202300308T1/it unknown
- 2017-09-22 FI FIEP17784089.9T patent/FI3515487T3/fi active
- 2017-09-22 PT PT177840899T patent/PT3515487T/pt unknown
- 2017-09-22 DK DK17787989.7T patent/DK3515946T5/da active
- 2017-09-22 IL IL265369A patent/IL265369B2/en unknown
- 2017-09-22 PL PL17787989.7T patent/PL3515946T3/pl unknown
- 2017-09-22 KR KR1020197011419A patent/KR102418667B1/ko active Active
- 2017-09-22 PL PL17784089.9T patent/PL3515487T3/pl unknown
- 2017-09-22 WO PCT/US2017/053114 patent/WO2018058003A1/en not_active Ceased
- 2017-09-22 JP JP2019515905A patent/JP7066691B2/ja active Active
- 2017-09-22 ES ES17784089T patent/ES2952735T3/es active Active
- 2017-09-22 AU AU2017339711A patent/AU2017339711B2/en active Active
- 2017-09-22 MD MDE20190826T patent/MD3515487T2/ro unknown
- 2017-09-22 JP JP2019515904A patent/JP7066690B2/ja active Active
-
2019
- 2019-03-13 ZA ZA2019/01557A patent/ZA201901557B/en unknown
- 2019-03-14 ZA ZA2019/01591A patent/ZA201901591B/en unknown
- 2019-03-14 PH PH12019500550A patent/PH12019500550A1/en unknown
- 2019-03-19 CL CL2019000712A patent/CL2019000712A1/es unknown
- 2019-03-19 PH PH12019500604A patent/PH12019500604A1/en unknown
- 2019-03-20 CL CL2019000726A patent/CL2019000726A1/es unknown
- 2019-04-22 CO CONC2019/0003967A patent/CO2019003967A2/es unknown
-
2020
- 2020-06-26 US US16/913,154 patent/US11485793B2/en active Active
-
2021
- 2021-10-08 CL CL2021002645A patent/CL2021002645A1/es unknown
-
2022
- 2022-09-26 US US17/953,114 patent/US20230272111A1/en active Pending
-
2023
- 2023-09-08 CL CL2023002690A patent/CL2023002690A1/es unknown